These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Dual acting anti-inflammatory drugs: a reappraisal. Bertolini A; Ottani A; Sandrini M Pharmacol Res; 2001 Dec; 44(6):437-50. PubMed ID: 11735348 [TBL] [Abstract][Full Text] [Related]
4. [Clinical application of cyclooxygenase-2 inhibitors]. Dzielska-Olczak M; Olczak S Pol Merkur Lekarski; 2001 Jun; 10(60):480-2. PubMed ID: 11503270 [TBL] [Abstract][Full Text] [Related]
5. Clinical pharmacology of selective COX-2 inhibitors. Capone ML; Tacconelli S; Sciulli MG; Patrignani P Int J Immunopathol Pharmacol; 2003; 16(2 Suppl):49-58. PubMed ID: 14552704 [TBL] [Abstract][Full Text] [Related]
6. Epidemiological and clinical aspects of nonsteroidal anti-inflammatory drugs and cancer risks. Moran EM J Environ Pathol Toxicol Oncol; 2002; 21(2):193-201. PubMed ID: 12086406 [TBL] [Abstract][Full Text] [Related]
7. Cyclo-oxygenase-2 inhibitors and the kidney: a case for caution. Noroian G; Clive D Drug Saf; 2002; 25(3):165-72. PubMed ID: 11945113 [TBL] [Abstract][Full Text] [Related]
8. "Selective" switching from non-selective to selective non-steroidal anti-inflammatory drugs. Bennett K; Teeling M; Feely J Eur J Clin Pharmacol; 2003 Nov; 59(8-9):645-9. PubMed ID: 12942226 [TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic and pharmacodynamic aspects of the ideal COX-2 inhibitor: a pharmacologist's perspective. Brune K; Neubert A Clin Exp Rheumatol; 2001; 19(6 Suppl 25):S51-7. PubMed ID: 11695253 [TBL] [Abstract][Full Text] [Related]
10. Comparison of the cyclooxygenase-1 inhibitory properties of nonsteroidal anti-inflammatory drugs (NSAIDs) and selective COX-2 inhibitors, using sensitive microsomal and platelet assays. Riendeau D; Charleson S; Cromlish W; Mancini JA; Wong E; Guay J Can J Physiol Pharmacol; 1997 Sep; 75(9):1088-95. PubMed ID: 9365818 [TBL] [Abstract][Full Text] [Related]
11. In vitro and in vivo pharmacological evidence of selective cyclooxygenase-2 inhibition by nimesulide: an overview. Famaey JP Inflamm Res; 1997 Nov; 46(11):437-46. PubMed ID: 9427063 [TBL] [Abstract][Full Text] [Related]
12. COX-2 inhibitors. What is their place? McGettigan P Aust Fam Physician; 2000 Sep; 29(9):847-52. PubMed ID: 11008387 [TBL] [Abstract][Full Text] [Related]
14. Anti-inflammatory drugs: new multitarget compounds to face an old problem. The dual inhibition concept. Celotti F; Laufer S Pharmacol Res; 2001 May; 43(5):429-36. PubMed ID: 11394934 [TBL] [Abstract][Full Text] [Related]
16. Future trends in the development of safer nonsteroidal anti-inflammatory drugs. Wolfe MM Am J Med; 1998 Nov; 105(5A):44S-52S. PubMed ID: 9855176 [TBL] [Abstract][Full Text] [Related]
17. Cyclo-oxygenase 2 function is essential for bone fracture healing. Simon AM; Manigrasso MB; O'Connor JP J Bone Miner Res; 2002 Jun; 17(6):963-76. PubMed ID: 12054171 [TBL] [Abstract][Full Text] [Related]